Keyphrases
Alanine Aminotransferase
25%
Compassionate Use
25%
Cystic Fibrosis
25%
De Novo Hepatitis B
25%
Fulminant Hepatitis
25%
Hepatic Decompensation
25%
Hepatic Fibrosis
25%
Hepatitis A
25%
Hepatitis B e Antigen (HBeAg)
25%
Hepatitis B Surface Antigen (HBsAg)
50%
Hepatitis B Treatment
100%
Hepatitis B Virus DNA
50%
Hepatitis B Virus Infection
100%
Histological Study
25%
Hyperoxaluria
25%
Immunoprophylaxis
25%
Infections in children
25%
Lamivudine
100%
Lamivudine Resistance
25%
Liver
25%
Liver Transplantation
100%
No Adverse Effect
25%
One-child
50%
Patient Demographics
25%
Polymerase Chain Reaction
25%
Serum Hepatitis
50%
Transplantation
50%
Medicine and Dentistry
Adverse Effect
20%
Alanine Aminotransferase
20%
Compassionate Use
20%
Cystic Fibrosis
20%
Decompensated Liver Cirrhosis
20%
Diseases
20%
Hepatitis A
20%
Hepatitis B
100%
Hepatitis B Antigen
40%
Hepatitis B Virus
40%
Hepatitis B(e) Antigen
20%
Hyperoxaluria
20%
Immunoprophylaxis
20%
Lamivudine
100%
Liver Fibrosis
20%
Liver Transplantation
100%
Patient Population
20%
Polymerase Chain Reaction
20%
Virus DNA
40%
Pharmacology, Toxicology and Pharmaceutical Science
Alanine Aminotransferase
20%
Cystic Fibrosis
20%
Decompensated Liver Cirrhosis
20%
Diseases
20%
Hepatitis A
20%
Hepatitis B
100%
Hepatitis B Antigen
40%
Hepatitis B Virus
40%
Hepatitis B(e) Antigen
20%
Hyperoxaluria
20%
Lamivudine
100%
Liver Fibrosis
20%
Virus DNA
40%